PATENT CLAIM ANALYSIS

Application Number: 16127560
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "019200"]

Abstract:
Disclosed herein are stabilized formulations of carfilzomib. The formulations exhibit increased storage stability relative to other formulations, and are simpler for health care providers to prepare and administer to patients.

Claim (Index 31):
A method of treating multiple myeloma, comprising administering to a patient in need thereof a liquid ready-to-use or ready-to-dilute composition, comprising carfilzomib or a pharmaceutically acceptable salt thereof, an organic solvent, and an acid stabilizer, wherein the composition, when stored for six months in a sealed, sterile vial at 60% RH at a temperature from 2-8\u00b0 C., contains no more than 1.0% total impurity, as measured by HPLC, wherein the acid stabilizer is selected from the group consisting of lactic acid, glycolic acid, 3-hydroxypropionic acid, 2-hydroxypropionic acid, 4-hydroxybutyric acid, 3-hydroxybutyric acid, 2-hydroxybutyric acid, malonic acid, succinic acid, malic acid, tartaric acid, citric acid, fumaric acid, and mixtures thereof.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 97.0
- Lexical Diversity: 1.26923
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15796021', '14023247', '15342457', '15824557', '13592228']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7061699082864812
- 35 USC 102 Novelty (BERT): 0.5388948807081887
- Combined Prediction Score: 0.6894424055286519
- Mean Citation Score: 228.586866
- Max Citation Score: 363.3687
- Similarity Product: 329.9955436573684

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test